Envestnet Asset Management Inc. Buys 49,821 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Envestnet Asset Management Inc. lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 24.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 250,194 shares of the medical equipment provider's stock after buying an additional 49,821 shares during the period. Envestnet Asset Management Inc. owned approximately 0.13% of Zimmer Biomet worth $26,428,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Wellington Management Group LLP lifted its stake in Zimmer Biomet by 12.3% during the third quarter. Wellington Management Group LLP now owns 37,068 shares of the medical equipment provider's stock valued at $4,001,000 after purchasing an additional 4,056 shares during the last quarter. MML Investors Services LLC boosted its position in shares of Zimmer Biomet by 103.6% in the 3rd quarter. MML Investors Services LLC now owns 37,566 shares of the medical equipment provider's stock valued at $4,055,000 after purchasing an additional 19,113 shares during the period. M&T Bank Corp raised its holdings in Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock worth $2,884,000 after buying an additional 8,709 shares during the period. Toronto Dominion Bank boosted its holdings in shares of Zimmer Biomet by 14.5% in the third quarter. Toronto Dominion Bank now owns 68,747 shares of the medical equipment provider's stock worth $7,421,000 after buying an additional 8,710 shares during the period. Finally, Sanctuary Advisors LLC raised its holdings in shares of Zimmer Biomet by 26.9% during the third quarter. Sanctuary Advisors LLC now owns 17,825 shares of the medical equipment provider's stock valued at $1,965,000 after acquiring an additional 3,776 shares during the period. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded up $0.96 during mid-day trading on Friday, reaching $97.90. 4,367,870 shares of the stock were exchanged, compared to its average volume of 1,650,696. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $19.37 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $96.58 and a fifty-two week high of $123.96. The firm has a 50-day simple moving average of $105.95 and a 200 day simple moving average of $106.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm posted $2.20 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Finally, Barclays dropped their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.